chemieunternehmen.com

Evotec SE announced today that the Company has extended and expanded its partnership with Bristol Myers Squibb in targeted protein degradation, originally signed in 2018. The initial collaboration has proven to be highly productive in generating a promising pipeline of molecular glue degraders. Based on this success, Bristol Myers Squibb and Evotec extend and expand this partnership for an additional 8 years with the goal to further broaden and deepen the strategic alliance. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bristol-myers-squibb-extend-and-expand-strategic-partnership-in-protein-degradation-6173

Evotec SE will announce its financial results for the first quarter of 2022 on Wednesday, 11 May 2022. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-to-announce-results-for-the-first-quarter-2022-on-11-may-2022-6169

Evotec SE announced today that the Company has made a strategic equity investment in Tubulis GmbH by participating in the company’s Series B financing round. Based in Munich, Germany, Tubulis specialises in the development of antibody drug conjugates (“ADCs”) by leveraging a set of proprietary technology platforms to develop these highly targeted therapeutics against solid tumours. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-makes-strategic-equity-investment-in-antibody-drug-conjugate-specialist-tubulis-6168

Evotec, together with BEOS, the leading asset manager and project developer of corporate real estate in Germany, celebrated the ground-breaking for Evotec’s fourth building at the Manfred-Eigen-Campus in Hamburg today. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/ground-breaking-for-evotecs-new-lab-building-in-hamburg-6166